Harm Reduction
Evidence-based strategies for risk reduction, set and setting, and safety guidelines for informed decision-making.
19 articles available
Start Here
Harm Reduction Basics
Risk-reduction strategies, evidence limitations, and crisis resources for informed decision-making.
10 minSet and Setting
The foundational harm reduction concept that emphasizes mindset and environment.
8 minDosing Guide
General reference ranges with potency uncertainty and risk limitations; not personal advice.
10 minContraindications & Drug Interactions
Documented and possible risks involving SSRIs, MAOIs, lithium, and heart conditions.
15 minCrisis & Difficult Experiences
Grounding techniques and support for challenging psychedelic experiences.
12 minCannabis & Psychedelics
Evidence-limited information on cannabis and psilocybin timing, interactions, and risks.
10 minIntegration Practices
Post-experience processing — journaling, therapy, and behavior change.
12 minMDMA Dosing Guide
General MDMA ranges, redosing risks, uncertainty, and limitations; not a body-weight recommendation.
15 minKetamine Safety & Clinical Use
Clinical distinctions, escalating risk signs, emergency guidance, and authoritative sources.
15 minLSD Dosing Guide
General LSD ranges, uncertain potency, tolerance, and testing limitations; not personal advice.
15 minDMT Dosing Guide
General DMT range education by route with variability and MAOI risks; not personal advice.
16 minIbogaine Dosing Guide
Published ibogaine protocol context, cardiac risk, and medical screening; not self-dosing guidance.
16 minMescaline & Peyote Dosing Guide
General mescaline ranges, uncertain cactus potency, and conservation context; not a recommendation.
14 minCannabis Dosing Guide
General cannabis ranges, delayed onset, variable response, interactions, and legal context.
14 minRelated Journal Articles
FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban Rivals’ Products Remains Pending
This morning, NRx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Abbreviated New Drug Application (ANDA) for its preservative-free ketamine produ...
From Ecstasy Rising to Peaking: Jordan Kronick on 20 Years Covering Psychedelics
Documentary filmmaker Jordan Kronick joins Joe to discuss Peaking: Psychedelics and the Pursuit of Happiness, a new psychedelic documentary that takes cameras into the dosing room across six psychedel...
Weekly Psychedelic Policy Briefing: October 12, 2026
FDA laid out how the first federally funded ibogaine trials could be run, with inpatient cardiac monitoring and a 10 mg/kg starting dose ceiling.
Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health
Kenneth Tupper joins Joe Moore for a wide-ranging conversation on harm reduction, drug education, British Columbia’s toxic drug crisis, ayahuasca policy, entheogenic education, and what psychedelic pu...
2026 Third Quarter — Legislative Wrap Up
Since the beginning of 2026, at least 23 states have introduced psychedelic legislation, signaling continued momentum and openness in how local and federal leaders address mental health, substance use...
By continuing to use this site, you agree to our Terms and Privacy Policy.

